Literature DB >> 34453903

MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin.

Juliana Montenegro Parente1, Marcela Maria Blascke de Mello1, Pedro Henrique Leite da Silva1, Ana Carolina Mieko Omoto2, Laena Pernomian1, Isadora Sousa de Oliveira3, Zabed Mahmud4, Rubens Fazan2, Eliane Candiani Arantes3, Richard Schulz5, Michele Mazzaron de Castro6.   

Abstract

PURPOSE: Cardiac transition from concentric (C-LVH) to eccentric left ventricle hypertrophy (E-LVH) is a maladaptive response of hypertension. Matrix metalloproteinases (MMPs), in particular MMP-2, may contribute to tissue remodeling by proteolyzing extra- and intracellular proteins. Troponin I and dystrophin are two potential targets of MMP-2 examined in this study and their proteolysis would impair cardiac contractile function. We hypothesized that MMP-2 contributes to the decrease in troponin I and dystrophin in the hypertensive heart and thereby controls the transition from C-LVH to E-LVH and cardiac dysfunction.
METHODS: Male Wistar rats were divided into sham or two kidney-1 clip (2K-1C) hypertensive groups and treated with water (vehicle) or doxycycline (MMP inhibitor, 15 mg/kg/day) by gavage from the tenth to the sixteenth week post-surgery. Tail-cuff plethysmography, echocardiography, gelatin zymography, confocal microscopy, western blot, mass spectrometry, in silico protein analysis and immunofluorescence were performed.
RESULTS: 6 out of 23 2K-1C rats (26%) had E-LVH followed by reduced ejection fraction. The remaining had C-LVH with preserved cardiac function. Doxycycline prevented the transition from C-LVH to E-LVH. MMP activity is increased in C-LVH and E-LVH hearts which was inhibited by doxycycline. This effect was associated with an increase in troponin I cleavage products and a decline in dystrophin in the left ventricle of E-LVH rats, which was prevented by doxycycline.
CONCLUSION: Hypertension causes increased cardiac MMP-2 activity which proteolyzes troponin I and dystrophin, contributing to the transition from C-LVH to E-LVH and cardiac dysfunction.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Dystrophin; Hypertension; Matrix metalloproteinase; Troponin I

Mesh:

Substances:

Year:  2021        PMID: 34453903     DOI: 10.1016/j.bcp.2021.114744

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

Review 1.  Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review).

Authors:  Aleksey M Chaulin
Journal:  Front Mol Biosci       Date:  2022-04-19

Review 2.  The Importance of Cardiac Troponin Metabolism in the Laboratory Diagnosis of Myocardial Infarction (Comprehensive Review).

Authors:  Aleksey M Chaulin
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

Review 3.  Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure.

Authors:  Pricila Rodrigues Gonçalves; Lisandra Duarte Nascimento; Raquel Fernanda Gerlach; Keuri Eleutério Rodrigues; Alejandro Ferraz Prado
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-25

4.  Doxycycline Attenuates Doxorubicin-Induced Cardiotoxicity by Improving Myocardial Energy Metabolism in Rats.

Authors:  Danielle Dantas; Amanda Gomes Pereira; Anderson Seiji Soares Fujimori; Ana Paula Dantas Ribeiro; Carol Cristina Vágula de Almeida Silva; Marina Gaiato Monte; Camila Renata Corrêa; Ana Angélica Fernandes; Silmeia Garcia Zanati Bazan; Paula Schmidt Azevedo; Marcos Ferreira Minicucci; Sergio Alberto Rupp de Paiva; Leonardo Antônio Mamede Zornoff; Bertha Furlan Polegato
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-08

Review 5.  Biology of Cardiac Troponins: Emphasis on Metabolism.

Authors:  Aleksey M Chaulin
Journal:  Biology (Basel)       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.